Nucleic acid and corresponding protein entitled 193P1E1B useful in treatment and detection of cancer

US7659377B2 · kind B2 · utility

Assignee

• Latency, LLC · US

Inventors

• Arthur B. Raitano · Los Angeles, US
• Pia M. Challita-Eid · Calabasas, US
• Mary Faris · Los Angeles, US
• Rene S. Hubert · Los Angeles, US
• Wangmao Ge · Tampa, US
• Aya Jakobovits · Beverly Hills, US

Key dates

• Filing date: Sep 9, 2008
• Grant date: Feb 9, 2010
• Expiry date: Sep 9, 2028

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A novel gene (designated 193P1E1B) and its encoded protein, and variants thereof, are described wherein 193P1E1B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 193P1E1B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 193P1E1B gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 191P1E1B can be used in active or passive immunization.